novel
coronaviru
also
call
novel
coronaviru
start
circul
among
human
around
decemb
widespread
global
pandem
diseas
caus
viru
call
highli
contagi
overal
mortal
rate
april
vaccin
antivir
avail
studi
report
discoveri
inhibitor
target
main
proteas
pro
use
fretbas
enzymat
assay
sever
inhibitor
includ
boceprevir
calpain
inhibitor
ii
xii
identifi
potent
activ
singledigit
submicromolar
valu
enzymat
assay
mechan
action
hit
character
use
enzym
kinet
studi
thermal
shift
bind
assay
significantli
four
compound
boceprevir
calpain
inhibitor
ii
xii
inhibit
viral
replic
cell
cultur
valu
rang
notabl
boceprevir
calpain
inhibitor
ii
xii
repres
novel
chemotyp
distinct
known
pro
inhibitor
overal
compound
identifi
herein
provid
promis
start
point
develop
therapeut
emerg
respiratori
diseas
start
circul
among
human
decemb
sinc
first
outbreak
china
unknown
origin
quickli
becam
global
pandem
april
death
among
confirm
case
countri
etiolog
pathogen
new
coronaviru
sever
acut
respiratori
syndrom
coronaviru
also
call
novel
coronaviru
name
indic
similar
sar
viru
caus
sever
respiratori
symptom
human
kill
peopl
among
infect
worldwid
share
sequenc
ident
sar
less
extent
middl
east
respiratori
syndrom
mer
envelop
positivesens
singlestrand
rna
viru
belong
coronaviru
also
contain
two
import
human
pathogen
sar
coronaviru
mer
coronaviru
mortal
rate
around
april
lower
sar
mer
howev
current
data
indic
contagi
larger
valu
sar
mer
result
higher
overal
death
toll
sar
mer
viru
current
spread
alarm
speed
europ
unit
state
current
antivir
vaccin
viral
genom
encod
number
structur
protein
eg
capsid
spike
glycoprotein
nonstructur
protein
eg
proteas
main
proteas
papainlik
proteas
helicas
rnadepend
rna
polymeras
accessari
protein
compound
target
anyon
viral
protein
might
potenti
antivir
drug
candid
studi
focu
viral
proteas
also
call
main
proteas
pro
aim
develop
potent
pro
inhibitor
antivir
pro
play
essenti
role
coronaviru
replic
biorxiv
preprint
digest
viral
polyprotein
site
appear
like
high
profil
target
antivir
drug
discoveri
pro
uniqu
substrat
prefer
glutamin
site
ser
ala
gli
featur
absent
close
relat
host
proteas
suggest
feasibl
achiev
high
select
target
viral
pro
develop
fluoresc
reson
energi
transfer
fret
base
enzymat
assay
pro
appli
screen
focus
librari
proteas
inhibitor
report
find
sever
hit
target
pro
mechan
action
vitro
antivir
activ
hit
also
evalu
cell
cultur
use
infecti
viru
overal
studi
provid
list
drug
candid
confirm
mechan
action
result
might
help
speed
drug
discoveri
effort
combat
compound
identifi
herein
repres
potent
select
pro
inhibitor
far
enzymat
inhibit
cellular
antivir
activ
result
pro
gene
strain
insert
vector
express
e
coli
histag
cterminu
pro
protein
purifi
ninta
column
high
puriti
fig
establish
fret
assay
condit
design
fret
base
substrat
use
sequenc
viral
polypeptid
junction
dabcylktsavlqsgfrkm
edan
test
pro
proteolyt
activ
buffer
differ
ph
found
pro
display
highest
activ
ph
buffer
fig
contain
mm
hepe
mm
nacl
mm
edta
mm
dtt
glycerol
follow
proteolyt
assay
conduct
use
ph
buffer
next
character
enzymat
activ
pro
measur
km
vmax
valu
nm
pro
mix
variou
concentr
fret
substrat
initi
veloc
measur
plot
substrat
concentr
curv
fit
michaelismenton
equat
gave
bestfit
valu
km
vmax
rfu
respect
fig
proteas
inhibitor
group
base
target
mechan
action
includ
proteasom
inhibitor
hiv
proteas
inhibitor
inhibitor
hcv
proteas
inhibitor
inhibitor
miscellan
serin
proteas
inhibitor
cathepsin
calpain
proteas
inhibitor
miscellan
cystein
proteas
inhibitor
matrix
metalloproteas
inhibitor
miscellan
proteas
inhibitor
inhibitor
preincub
nm
pro
minut
presenc
mm
dtt
addit
fret
substrat
addit
dtt
quench
nonspecif
thiol
reactiv
compound
also
ensur
pro
reduc
condit
compound
test
except
compound
test
due
fluoresc
background
encouragingli
four
inhibitor
show
inhibit
pro
among
hit
simeprevir
boceprevir
narlaprevir
hcv
serin
proteas
inhibitor
compound
inhibit
proteasom
calpain
tabl
list
proteas
inhibitor
test
pro
primari
fret
assay
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
aspart
proteas
inhibitor
hcv
proteas
serin
proteas
inhibitor
miscellan
cystein
proteas
inhibitor
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
calcul
initi
veloc
compound
normal
dmso
control
result
averag
standard
deviat
two
repeat
given
encourag
result
primari
screen
character
four
hit
consortium
assay
includ
doserespons
titrat
thermal
shift
bind
assay
tsa
counter
screen
assay
two
viral
cystein
proteas
enteroviru
proteas
cystein
proteas
hcv
proteas
inhibitor
boceprevir
narlaprevir
inhibit
pro
valu
respect
tabl
potent
simeprevir
compound
also
show
strong
bind
toward
pro
shift
melt
temperatur
protein
c
respect
despit
potent
inhibit
hcv
serin
proteas
cystein
pro
boceprevir
narlaprevir
inhibit
proteas
suggest
nonspecif
cystein
proteas
inhibitor
calpain
inhibitor
valu
pro
activ
proteas
bind
pro
also
confirm
tsa
assay
c
light
promis
result
calpain
inhibitor
pursu
test
calpain
cathepsin
inhibitor
commerci
avail
tabl
compound
includ
initi
librari
advanc
clinic
studi
among
seri
analog
calpain
inhibitor
ii
xii
potent
also
includ
two
wellknown
viral
proteas
inhibitor
rupintrivir
secondari
screen
investig
veterinari
drug
develop
felin
infecti
periton
fip
design
target
viral
proteas
potent
antivir
activ
multipl
virus
includ
mer
fipv
noroviru
rupintrivir
develop
rhinoviru
antivir
target
viral
proteas
discontinu
clinic
trial
due
side
effect
studi
found
potent
pro
inhibitor
valu
shift
melt
curv
pro
c
upon
bind
contrast
rupintrivir
activ
pro
previou
report
also
show
rupintrivir
activ
sarscov
pro
pro
compound
activ
proteas
show
potent
inhibit
proteas
consist
previous
report
result
plot
valu
log
scale
inhibitor
pro
fret
enzymat
assay
melt
temperatur
shift
thermal
shift
bind
assay
fig
linear
correl
observ
r
linear
regress
fit
suggest
direct
correl
enzymat
inhibit
protein
bind
potent
enzym
inhibitor
also
bind
protein
higher
affin
stabil
pro
thermal
denatur
also
compound
concentr
depend
fig
correl
inhibit
efficaci
thermal
shift
bind
assay
data
tabl
use
plot
r
fit
b
dosedepend
melt
temperatur
tm
shift
elucid
mechan
action
hit
pro
focu
five
potent
compound
priorit
primari
secondari
screen
includ
boceprevir
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
proceed
beyond
minut
therefor
chose
first
minut
progress
curv
curv
fit
fig
middl
column
fit
progress
curv
presenc
differ
concentr
twostep
morrison
equat
equat
method
section
bind
pro
equilibrium
dissoci
constant
inhibitor
ki
nm
first
step
initi
bind
slower
coval
bond
form
pro
second
reaction
rate
constant
result
overal
valu
x
fig
howev
tri
fit
proteolyt
progress
curv
boceprevir
calpain
inhibitor
ii
xii
use
twostep
reaction
mechan
could
obtain
accur
valu
second
rate
constant
presum
due
signific
substrat
deplet
equilibrium
ei
ei
lead
small
valu
accordingli
four
inhibitor
test
hypothesi
inhibit
enzymat
activ
pro
lead
inhibit
viral
replic
perform
cellular
antivir
assay
five
promis
hit
first
test
cellular
cytotox
compound
multipl
cell
line
tabl
boceprevir
calpain
inhibitor
ii
well
toler
valu
cell
line
test
cytotox
cell
valu
less
except
cell
calpain
inhibitor
xii
accept
cellular
cytotox
valu
cell
line
test
coronavirus
caus
three
epidemicspandem
past
twenti
year
includ
sar
mer
ongo
pandem
scientist
research
around
globe
race
find
effect
vaccin
antivir
drug
viral
polymeras
inhibitor
remdesivir
hold
greatest
promis
current
evalu
sever
clinic
trial
hiv
drug
combin
lopinavir
ritonavir
recent
fail
clinic
trial
signific
therapeut
efficaci
observ
address
unmet
medic
need
initi
drug
repurpos
screen
identifi
potent
inhibitor
pro
collect
fdaapprov
proteas
inhibitor
pro
shown
valid
antivir
drug
target
sar
mer
pro
share
high
sequenc
similar
sar
less
extent
mer
reason
inhibit
enzymat
activ
pro
similarli
prevent
viral
replic
notic
find
studi
includ
boceprevir
potent
pro
inhibitor
contain
reactiv
warhead
boceprevir
calpain
inhibitor
xii
aldehyd
calpain
inhibitor
ii
aldehyd
prodrug
bisulfit
result
suggest
reactiv
warhead
might
essenti
pro
inhibit
compound
identifi
studi
repres
potent
select
hit
report
far
superior
recent
report
pro
inhibitor
ebselen
tabl
asid
posit
result
also
show
ritonavir
lopinavir
summari
studi
identifi
sever
potent
pro
inhibitor
potent
enzymat
inhibit
well
potent
cellular
antivir
activ
develop
base
hit
might
lead
clinic
use
antivir
use
either
alon
combin
polymeras
inhibitor
remdesivir
mean
achiev
potenti
synerg
antivir
effect
well
suppress
drug
resist
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
maintain
rpmi
medium
medium
supplement
fetal
bovin
serum
fb
penicillinstreptomycin
antibiot
cell
kept
atmospher
strain
obtain
world
refer
center
emerg
virus
arbovirus
wrceva
express
vector
previous
describ
pro
fret
substrat
dabcylktsavlqsgfrkm
edan
synthes
solidphas
synthesi
iter
cycl
coupl
deprotect
use
previous
optim
procedur
specif
chemmatrix
rinkamid
resin
use
typic
coupl
condit
equiv
amino
acid
equiv
hatu
equiv
diea
dmf
minut
c
deprotect
piperazin
plu
hobt
use
mixtur
heat
c
minut
peptid
cleav
resin
use
tfa
tri
crude
peptid
precipit
ether
remov
tfa
final
peptid
purifi
prepar
hplc
purifi
identifi
peptid
confirm
analyt
hplc
puriti
mass
spectrometri
p
fluoresc
signal
time
background
signal
time
zero
vs
k
repres
respect
initi
veloc
final
steadyst
veloc
appar
firstord
rate
constant
establish
equilibrium
ei
ei
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
commonli
use
evalu
efficaci
coval
inhibitor
observ
substrat
deplet
proteolyt
reaction
progress
longer
min
therefor
first
min
progress
curv
use
curv
fit
figur
middl
column
studi
could
accur
determin
proteas
inhibitor
calpain
inhibitor
ii
boceprevir
calpain
inhibitor
xii
due
slow
case
signific
substrat
deplet
establish
equilibrium
ei
ei
case
ki
cytotox
measur
mdck
vero
cell
cytotox
cpe
assay
seed
grown
overnight
atmospher
confluenc
next
day
cell
wash
pb
buffer
dmem
fb
variou
concentr
proteas
inhibitor
ad
well
hr
addit
proteas
inhibitor
cell
stain
ml
neutral
red
h
neutral
red
uptak
measur
absorb
nm
use
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
multiskan
fc
micropl
photomet
thermo
fisher
scientif
valu
calcul
bestfit
curv
use
graphpad
prism
softwar
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cell
day
infect
data
viru
inhibitori
concentr
determin
regress
analysi
influenza
viru
plaqu
reduct
assay
plaqu
assay
perform
accord
previous
publish
procedur
